ERBB2 and gastroesophageal junction adenocarcinoma: Since the initiation of this trial, there have been major advances in the treatment of metastatic HER2-negative gastric/GEJ adenocarcinoma with the addition of immune checkpoint inhibitors to chemotherapy in the frontline setting.